Fig. 2. Overall survival. (A) Total patients; Upper line, T1,T2 (n = 18; 40.8 months, 95% confidence interval [CI], 21.56-60.10) and lower line, T3, T4 (n = 15; 32.3 months, 95% CI, 20.46-44.20). P = 0.385. (B) Patients with locally advanced esophageal cancer; Upper line, TLG ≤ 232.98 (n = 14; 46.9 months, 95% CI, 33.50-60.26) and lower line, TLG > 232.98 (n = 19; 25.3 months, 95% CI, 8.37-42.28). P = 0.003. (C) Patients with locally advanced esophageal cancer; Upper line, MTV ≤ 44.70 cm³ (n = 17; 39.0 months, 95% CI, 26.37-51.63) and lower line, MTV > 44.70 cm³ (n = 16; 34.6 months, 95,% CI 15.10-54.01). P = 0.054. (D) Patients with locally advanced esophageal cancer; Upper line, SUVmean ≤ 5.70 (n = 16; 43.0 months, 95% CI, 21.11-64.80) and lower line, SUVmean > 5.70 (n = 17; 31.0 months, 95% CI, 17.10-44.89). P = 0.963.